Moleculin Biotech Stock Today
| MBRX Stock | USD 2.73 0.10 3.53% |
Performance3 of 100
| Odds Of DistressLess than 36
|
Moleculin Biotech is trading at 2.73 as of the 25th of November 2024; that is 3.53 percent decrease since the beginning of the trading day. The stock's open price was 2.83. Moleculin Biotech has about a 36 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Moleculin Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of February 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of June 2016 | Category Healthcare | Classification Health Care |
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. The company has 3 M outstanding shares of which 122.38 K shares are now shorted by private and institutional investors with about 5.63 trading days to cover. More on Moleculin Biotech
Moving against Moleculin Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Moleculin Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman, CoFounder | Walter Klemp | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMoleculin Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Moleculin Biotech's financial leverage. It provides some insight into what part of Moleculin Biotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Moleculin Biotech (MBRX) is traded on NASDAQ Exchange in USA. It is located in 5300 Memorial Drive, Houston, TX, United States, 77007 and employs 18 people. Moleculin Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.2 M. Moleculin Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3 M outstanding shares of which 122.38 K shares are now shorted by private and institutional investors with about 5.63 trading days to cover.
Moleculin Biotech currently holds about 58 M in cash with (24.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.03.
Check Moleculin Biotech Probability Of Bankruptcy
Ownership AllocationMoleculin Biotech secures 3.3 % of its outstanding shares held by insiders and 15.34 % owned by institutional investors.
Check Moleculin Ownership Details
Moleculin Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Sandy Spring Bank | 2024-06-30 | 89.0 | |
| Cva Family Office, Llc | 2024-09-30 | 34.0 | |
| Bank Of America Corp | 2024-06-30 | 28.0 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 23.0 | |
| North Star Investment Management Corp | 2024-09-30 | 17.0 | |
| Royal Bank Of Canada | 2024-06-30 | 10.0 | |
| Jpmorgan Chase & Co | 2024-06-30 | 6.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Goss Wealth Management Llc | 2024-06-30 | 0.0 | |
| Armistice Capital, Llc | 2024-09-30 | 290 K | |
| Vanguard Group Inc | 2024-09-30 | 71.4 K |
Moleculin Biotech Historical Income Statement
Moleculin Stock Against Markets
Moleculin Biotech Corporate Management
| Louis Ploth | Independent Advisor | Profile | |
| ScD MD | Senior Officer | Profile | |
| Jacqueline Northcut | Consultant | Profile | |
| Donald Picker | Chief Officer | Profile | |
| Waldemar Priebe | Founding CoFounder | Profile |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.